Cryo-EM structure of human LRRC15 reveals the basis of therapeutic antibody recognition
This study presents the first high-resolution cryo-EM structure of the human LRRC15 receptor complexed with the therapeutic antibody samrotamab, revealing a unique lateral binding mode that preserves the receptor's signaling surface and guiding the design of new minibinders targeting the previously unexplored concave face.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Imagine a protein called LRRC15 as a bent, curved archway standing on the surface of certain cells. This archway is made of repeating segments, like a chain of links, and it has a "face" (the concave side) and a "back" (the convex side). In many tough-to-treat cancers, this archway is built in huge numbers, acting like a shield that helps the tumor resist therapy.
Scientists have developed a powerful drug, samrotamab, which is designed to find and latch onto this archway to deliver a toxic payload directly to the cancer cells. However, until now, nobody knew exactly how this drug grabbed the archway. It was like trying to fix a lock without ever seeing the key or the tumblers.
In this study, researchers used two high-tech tools—like a super-precise camera (cryo-EM) and a molecular "tape measure" (hydrogen-deuterium exchange)—to take a crystal-clear 3D picture of the drug holding onto the archway.
Here is what they discovered, using simple analogies:
- The Grip: The drug doesn't grab the archway by its main "face" (the concave surface). Instead, it grabs the archway from the side, near the base where it connects to the cell membrane. Think of it like a person hugging a curved wall from the side, rather than pressing their face against the center of the wall.
- The Open Face: Because the drug hugs the side, the main "face" of the archway remains completely exposed and open. It's as if the drug is holding the handle of a door but leaving the door itself wide open for other things to walk through. This explains why the drug can stick to the cell without necessarily blocking the signals the cell needs to send.
- New Keys: Now that the scientists have a perfect map of this "open face," they used computer simulations to design brand-new, tiny keys (called minibinders) specifically shaped to fit into that empty space. They successfully created several of these new keys, and they fit the lock with incredible precision (nanomolar affinity).
In short: This paper is the first time anyone has seen the 3D blueprint of this cancer-related protein. It reveals that the current drug hugs the side of the protein, leaving the front open. This discovery not only explains how the current drug works but also provides a blueprint for engineers to build new, even better tools to target that open front surface in the future.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.